An insight into Science Creates
Founded by exited entrepreneurs, Science Creates is a Deep Tech ecosystem that enables scientists and engineers to turn their groundbreaking discoveries into disruptive businesses that can revolutionise the health of people and the planet.
We support our startup community with specialised lab space, expert training and mentoring, a network of partner organisations, and access to investment opportunities.
Through our independent charity and public events, we inspire the next generation of scientists and entrepreneurs.





Our ethos
We believe the next big breakthroughs will emerge at the intersection of fields like quantum, AI, and biotechnology — and that spinouts are the most powerful way to turn those innovations into global impact.
The first step is empowering those at the forefront of knowledge with the right infrastructure, training, resources and investment.
Science Creates is laying the foundations for bold ideas and innovation to thrive and scale, nationwide.
Designed for flexibility, OMX, our new 30,000 sq ft of lab, office, and meeting space for startups and scaleups is set to open in March 2026 in Bristol’s city centre.
We currently welcome applications from service providers working in legal, IT, grants, cloud, bespoke software and marketing.
We invest in Deep Tech at the pre-seed and seed stages — and our endgame is global impact.
.webp)


Our focus
Deep Tech refers to innovations based on major breakthroughs in science and engineering, often built on years of research and proprietary technology to solve global challenges. Unlike regular tech, it focuses on transformative, long-term solutions in fields like AI, quantum, synthetic biology and advanced materials.
Deep Tech has the power to revolutionise industries, create new markets, and improve lives. From AI-driven healthcare to sustainable energy and quantum technologies, it tackles critical global issues.
We specialise in Deep Tech for its potential to drive systemic change and create significant impact, providing patient capital and strategic support to turn groundbreaking ideas into scalable businesses.

Transdermal Diagnostics is pioneering the development of bio-wearables that enhance the prevention, diagnosis and management of chronic conditions like diabetes. Its unique sensing technology aims to create the world’s first needle-free continuous monitor for glucose and other health biomarkers. By analysing hair follicles, the adhesive skin patch and transmitter wirelessly communicate information straight to a smartphone app, facilitating a transformative shift in patient care and quality of life for those with diabetes.

PentaBind is designing high performance aptamers as therapeutic delivery vehicles and active ingredients. It uses generative artificial intelligence models, supported by wet-laboratory data generation processes, to help produce aptamer drugs that are easy to design, highly selective and ‘invisible’ to the immune system. Unlike many RNA drugs targeting mRNA, its aptamers overcome high gene turnover issues and endosomal escape challenges for effective tumour penetration.

Excellio is pioneering breakthroughs in targeted drug delivery using the extracellular vesicles, exosomes. Its innovative technology enables advanced biological therapeutics to reach previously unaddressed targets by equipping exosomes with tissue-specific GPS systems. This approach aims to redefine the landscape of precision medicine, improving treatment efficacy and safety by optimising cargo delivery and enhancing clinical performance.



Available for hire for those working in the innovation sector, our versatile spaces can welcome a variety of events.
